Switch theme
Sign up to access all valuation multiples
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
2015
738
LTM Revenue $804M
LTM EBITDA $268M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GoodRx has a last 12-month revenue (LTM) of $804M and a last 12-month EBITDA of $268M.
In the most recent fiscal year, GoodRx achieved revenue of $792M and an EBITDA of $154M.
GoodRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GoodRx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $804M | XXX | $792M | XXX | XXX | XXX |
| Gross Profit | $755M | XXX | $744M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $268M | XXX | $154M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $201M | XXX | $65.8M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $35.8M | XXX | $16.4M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $43.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GoodRx's stock price is $4.
GoodRx has current market cap of $1.4B, and EV of $1.6B.
See GoodRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.4B | XXX | XXX | XXX | XXX | $0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GoodRx has market cap of $1.4B and EV of $1.6B.
GoodRx's trades at 2.1x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate GoodRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GoodRx has a P/E ratio of 39.1x.
See valuation multiples for GoodRx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 8.2x | XXX | 24.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 39.1x | XXX | 85.5x | XXX | XXX | XXX |
| EV/FCF | 11.6x | XXX | 14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGoodRx's last 12 month revenue growth is 4%
GoodRx's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
GoodRx's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GoodRx's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GoodRx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 60% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Star Health Insurance | XXX | XXX | XXX | XXX | XXX | XXX |
| Hapvida | XXX | XXX | XXX | XXX | XXX | XXX |
| Qualicorp | XXX | XXX | XXX | XXX | XXX | XXX |
| Accolade | XXX | XXX | XXX | XXX | XXX | XXX |
| AIX Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GoodRx acquired XXX companies to date.
Last acquisition by GoodRx was XXXXXXXX, XXXXX XXXXX XXXXXX . GoodRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GoodRx founded? | GoodRx was founded in 2015. |
| Where is GoodRx headquartered? | GoodRx is headquartered in United States of America. |
| How many employees does GoodRx have? | As of today, GoodRx has 738 employees. |
| Who is the CEO of GoodRx? | GoodRx's CEO is Ms. Wendy Barnes. |
| Is GoodRx publicy listed? | Yes, GoodRx is a public company listed on NAS. |
| What is the stock symbol of GoodRx? | GoodRx trades under GDRX ticker. |
| When did GoodRx go public? | GoodRx went public in 2020. |
| Who are competitors of GoodRx? | Similar companies to GoodRx include e.g. Star Health Insurance, Hapvida, Qualicorp, Accolade. |
| What is the current market cap of GoodRx? | GoodRx's current market cap is $1.4B |
| What is the current revenue of GoodRx? | GoodRx's last 12 months revenue is $804M. |
| What is the current revenue growth of GoodRx? | GoodRx revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of GoodRx? | Current revenue multiple of GoodRx is 2.0x. |
| Is GoodRx profitable? | Yes, GoodRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GoodRx? | GoodRx's last 12 months EBITDA is $268M. |
| What is GoodRx's EBITDA margin? | GoodRx's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of GoodRx? | Current EBITDA multiple of GoodRx is 6.1x. |
| What is the current FCF of GoodRx? | GoodRx's last 12 months FCF is $142M. |
| What is GoodRx's FCF margin? | GoodRx's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of GoodRx? | Current FCF multiple of GoodRx is 11.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
